Skip to main content

Advertisement

SpringerLink
Log in

Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival

  • Original Article
  • Published:
Tumor Biology

Abstract

The pre-mRNA splicing regulator serine-arginine protein kinase 1 (SRPK1) promotes cancer development and various pathophysiological processes. However, the clinical relevance of SRPK1 in hepatocellular carcinoma (HCC) is not clear. This study investigates the expression and prognostic value of SRPK1 in HCC. We found that SRPK1 expression was significantly upregulated at the mRNA and protein level in all HCC cell lines or HCC tissue samples compared with the hepatic cell line or matched noncancerous tissue samples, respectively. Higher SRPK1 expression significantly correlated with clinical staging (p = 0.031), survival time (p = 0.004), and gender (p = 0.011) of HCC patients. Together, our study showed that SRPK1 is overexpressed in HCC and may be a promising indicator of prognosis for HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Scott T. Eblen: Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol. 2012;8:1063–72. doi:10.1016/j.bcp.2011.12.041.

    Google Scholar 

  2. Graveley BR. Sorting out the complexity of SR protein functions. RNA. 2000;9:1197–211.

    Article  Google Scholar 

  3. Papoutsopoulou S, Nikolakaki E, Chalepakis G, Kruft V, Chevaillier P, Giannakouros T. SR protein-specific kinase 1 is highly expressed in testis and phosphorylates protamine 1. Nucleic Acids Res. 1999;27:2972–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007;5:2072–80.

    Article  Google Scholar 

  5. Wu Q, Chang Y, Zhang L, Zhang Y, Tian T, Feng G, et al. SRPK1 dissimilarly impacts on the growth, metastasis, chemosensitivity and angiogenesis of glioma in normoxic and hypoxic conditions. J Cancer. 2013;9:727–35. doi:10.7150/jca.7576. eCollection 2013.

    Article  Google Scholar 

  6. Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006;1:225–35.

    Google Scholar 

  7. Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, et al. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in cisplatin cytotoxicity in vitro. PLoS One. 2012;7(12):e51030. doi:10.1371/journal.pone.0051030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem. 2010;285(8):5532–40. doi:10.1074/jbc.M109.074930.

    Article  CAS  PubMed  Google Scholar 

  9. Gammons MVR, Dick AD, Harper SJ, Bates DO. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013;54:5797–806. doi:10.1167/iovs.13-11634.

    Article  CAS  PubMed  Google Scholar 

  10. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2002;2005(55):74–108.

    Google Scholar 

  11. Luca Faloppi B, Mario Scartozzi A, Elena Maccaroni B, Marzia Di Pietro Paolo C, Rossana Berardi A, Michela Del Prete A, Stefano C. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-taylored therapeutic options. Cancer Treat Rev 2011;(37):169–177.

  12. Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett. 2009;286:5–8.

    Article  CAS  PubMed  Google Scholar 

  13. Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29(1-2):130–43.

    Article  PubMed  Google Scholar 

  14. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma An audit of 343 patients. Ann Surg. 1995;221:291–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536–43.

    PubMed  PubMed Central  Google Scholar 

  16. Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, et al. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012;47(4):421–6. doi:10.1007/s00535-011-0492-9.

    Article  PubMed  Google Scholar 

  17. Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. doi:10.1186/1479-5876-9-166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 2001;25:402–8.

    Article  CAS  PubMed  Google Scholar 

  19. Baig S. Gender disparity in infections of Hepatitis B virus. S J Coll Physicians Surg Pak. 2009;19(9):598–600.

  20. Pawlik TM, Delman KA, Vauthey J-N, Nagorney DM, Ng IO, Ikai I, et al. Tumor Size Predicts Vascular Invasion and Histologic Grade: Implications for Selection of Surgical Treatment for Hepatocellular Carcinoma. Liver Transpl. 2005;9:1086–92.

    Article  Google Scholar 

  21. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006;7:3819–27.

    Article  Google Scholar 

  22. Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, et al. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem Soc Trans. 2012;40(4):831–5. doi:10.1042/BST20120051.

    Article  CAS  PubMed  Google Scholar 

  23. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011;20(6):768–80. doi:10.1016/j.ccr.2011.10.016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;14:4123–31.

    Google Scholar 

  25. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans. 2009;37:1207–13. doi:10.1042/BST0371207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A. 2006;30:11329–33.

    Article  Google Scholar 

  27. Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother. 2010;8:3179–86. doi:10.1128/AAC.00113-10.

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported by the Science and Technology Department of Guangzhou (No. 2014 J4100063), National Science Foundation of China (No. 81101317), and Science and Technology Planning Project of Guangdong Province, China (No. 2013B021800040)

Authors’ contributions

GS, JZ, HJ, and WFX devised the study. JZ, HJ, YZJ, XYT, and PYL selected participants, oversaw diagnostic evaluations, and directed YJ, XJ, and PYL studies and analyses. HYJ and XWY performed the statistical analyses. GS wrote the manuscript and all authors participated in reviewing and editing the manuscript.

Author information

Author notes

    Authors and Affiliations

    1. Department of Interventional Radiology and Vascular Anomalies, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9th Jinsui Road, Postal Code 510000, Guangzhou, Guangdong, 510623, People’s Republic of China

      Jing Zhang, Hua Jiang, Yizhou Jiang, Xiaoyun Tan, Peiying Liu & Gang Shen

    2. Department of Clinical Examination, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510260, People’s Republic of China

      Hongyun Jia

    3. Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510260, People’s Republic of China

      Xuewei Yang

    4. Department of General Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

      Wenfei Xia

    Authors
    1. Jing Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Hua Jiang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Wenfei Xia
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Yizhou Jiang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Xiaoyun Tan
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Peiying Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Hongyun Jia
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Xuewei Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Gang Shen
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Gang Shen.

    Additional information

    Jing Zhang, Hua Jiang and Wenfei Xia contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Zhang, J., Jiang, H., Xia, W. et al. Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival. Tumor Biol. 37, 283–290 (2016). https://doi.org/10.1007/s13277-015-3771-x

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-3771-x

    Keywords

    Search

    Navigation